GSK plc Buys Back Own Shares
Ticker: GLAXF · Form: 6-K · Filed: Sep 5, 2025 · CIK: 1131399
| Field | Detail |
|---|---|
| Company | Gsk PLC (GLAXF) |
| Form Type | 6-K |
| Filed Date | Sep 5, 2025 |
| Risk Level | low |
| Pages | 10 |
| Reading Time | 12 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-buyback, stock-transaction
TL;DR
GSK is buying back its own stock via Merrill Lynch.
AI Summary
GSK plc announced on September 5, 2025, that it purchased a certain number of its own ordinary shares through its corporate stockbroker, Merrill Lynch International. The filing does not specify the exact number of shares or the total dollar amount involved in these transactions.
Why It Matters
Share buybacks can signal management's confidence in the company's valuation and potentially increase earnings per share.
Risk Assessment
Risk Level: low — This filing is a routine report of share transactions and does not contain significant new financial or strategic information.
Key Players & Entities
- GSK plc (company) — Company making share purchases
- Merrill Lynch International (company) — Corporate stockbroker executing share purchases
- September 2025 (date) — Period of report for share transactions
FAQ
What was the specific date of the share purchase?
The filing states 'Date of purchase:' but does not provide a specific date.
How many ordinary shares did GSK plc purchase?
The filing indicates that a 'certain number' of shares were purchased but does not specify the quantity.
What was the total dollar amount spent on the share buyback?
The filing does not disclose the total dollar amount of the share repurchases.
Who is GSK plc's corporate stockbroker for these transactions?
GSK plc is acting through its corporate stockbroker, Merrill Lynch International.
What is the par value of GSK plc's ordinary shares?
The ordinary shares are of 31¼ pence each.
Filing Stats: 2,911 words · 12 min read · ~10 pages · Grade level 3.7 · Accepted 2025-09-05 07:15:46
Filing Documents
- a1118y.htm (6-K) — 2558KB
- 0001654954-25-010429.txt ( ) — 2559KB
From the Filing
IN OWN SHARES a1118y   UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   Form 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934     For the month of September 2025   Commission File Number 001-15170     GSK plc (Translation of registrant's name into English)     79 New Oxford Street, London, WC1A 1DG (Address of principal executive office)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.   Form 20-F . . . .X. . . . Form 40-F . . . . . . . .       Transaction in own shares   GSK plc (the " Company ") announces today   acting through its corporate stockbroker, Merrill Lynch International (the " Broker "), it has purchased the following number of the Company's ordinary shares of  31¼  pence each.   Date of purchase:   04 September 2025   Aggregate number of ordinary shares of  31¼  pence each purchased:   284,800   Lowest price paid per share (GBp):   1,451.00p   Highest price paid per share (GBp):   1,472.50p   Volume-weighted average price paid per share (GBp):   1,464.66p     The purchased shares will be held as Treasury shares.   Such purchase forms part of the Company's existing buyback programme and was effected pursuant to the non-discretionary agreement entered into with the Broker on 4 June 2025, as announced on 4 June 2025. Since 4 June 2025 the Company has purchased 27,315,467 ordinary shares.   Following the above purchase, the Company will hold 245,449,850 ordinary shares in treasury and have 4,069,946,246 ordinary shares in issue (excluding Treasury shares).   The total number of voting rights in the Company is   4,069,946,246. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.   The Company confirms that, in accordance with DTR 5.5.1R, following the above purchase the percentage of voting rights attributable to the ordinary shares held in treasury is   6.03 per cent.   The table below contains detailed information of the individual trades made by the Broker on the London Stock Exchange and the CBOE Europe Limited recognised investment exchange (through its order books having market identification codes CHIX or BATE) as part of the buyback programme.     Schedule of Purchases   Shares purchased:     GSK plc (ISIN: GB00BN7SWP63)   Date of purchases:    04 September 2025   Investment firm:       Merrill Lynch International     Aggregated information per trading venue:   Venue   Number of ordinary shares purchased   Highest price paid (per ordinary share) (GBp)   Lowest price paid (per ordinary share) (GBp)   Volume weighted average price paid (per ordinary share) (GBp)   London Stock Exchange (XLON)   284,800   1,472.50p   1,451.00p   1,464.66p   CBOE (CHIX)   0   -   -   -   CBOE (BATE)   0   -   -   -       Individual transactions:   Number ofShares   Price per Share (GBp)   Tradingvenue   Date oftransaction   Time oftransaction   Transaction reference number   49   1,457.00    XLON   04-Sep-2025   08:00:03   0XL0640000000000ARCN3S   50   1,457.00    XLON   04-Sep-2025   08:00:03   0XL0640000000000ARCN3T   51   1,457.00    XLON   04-Sep-2025   08:00:03   0XL0670000000000ARCN49   51   1,457.00    XLON   04-Sep-2025   08:00:03   0XL06A0000000000ARCN60   53   1,457.00    XLON   04-Sep-2025   08:00:03   0XL0610000000000ARCMTI   40   1,455.50    XLON   04-Sep-2025   08:00:04   0XL06A0000000000ARCN7A   952   1,456.00    XLON   04-Sep-2025   08:00:04   0XL0614000000000ARCN72   1,399   1,456.00    XLON   04-Sep-2025   08:00:04   0XL06140000000